

AD _____

AWARD NUMBER: W81XWH-08-1-0377

TITLE: Unraveling the Molecular Mechanism(s) Underlying ER+/PR- Breast
Tumorigenesis Using a Novel Genetically Engineered Mouse Model

PRINCIPAL INVESTIGATOR: Hua Xiao

CONTRACTING ORGANIZATION: Michigan State University
East Lansing, MI 48824

REPORT DATE: September 2009

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				<i>Form Approved</i> OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE 1 September 2009		2. REPORT TYPE Annual		3. DATES COVERED 1 Sep 2008 – 31 Aug 2009	
4. TITLE AND SUBTITLE Unraveling the Molecular Mechanism(s) Underlying ER+/PR- Breast Tumorigenesis Using a Novel Genetically Engineered Mouse Model				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-08-1-0377	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Hua Xiao E-Mail: xiaoh@msu.edu				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Michigan State University East Lansing, MI 48824				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT Estrogen-receptor alpha (ERα)-positive Progesterone receptor negative (ER+/PR-) breast ductal carcinomas comprise approximate 15-25% of human breast cancers. However, molecular mechanisms underlying the development of this subtype of breast cancer remain poorly understood. Using genetically-engineered Tip30 knockout mice generated in our laboratory, we previously demonstrated that Tip30 deletion results in development of tumors in several tissues and ductal hyperplasia in the mammary glands. This project is to study the molecular mechanism(s) underlying ER+/PR- breast tumorigenesis. Specifically, we proposed to determine genetic and epigenetic alterations in the initiation and progression of ER+/PR- mammary tumors arising in Tip30-/-/MMTV-neu mice. Here we show that Tip30 deletion in MMTV-Neu mice significantly accelerates the formation of ER+/PR- mammary tumors. An unbiased DNA microarray analysis revealed that Tip30 deletion resulted in increased activation of cAMP-mediated signaling, EGF signaling, IGF signaling and PI3K/AKT signaling in ER+/PR- mammary tumors. Taken together, our data suggest that inactivation of TIP30 may contribute to the development of ER-positive and PR-negative breast cancers through activation of EGF and IGF signaling pathways.					
15. SUBJECT TERMS Estrogen receptor, Progesterone receptor, breast cancer, tumorigenesis					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT UU	18. NUMBER OF PAGES 8	19a. NAME OF RESPONSIBLE PERSON USAMRMC
a. REPORT U	b. ABSTRACT U	c. THIS PAGE U			19b. TELEPHONE NUMBER (include area code)

Table of Contents

	<u>Page</u>
Introduction.....	4
Body.....	4-6
Key Research Accomplishments.....	7
Reportable Outcomes.....	7
Conclusion.....	7
References.....	7-8
Appendices.....	

Introduction:

To date, the mechanisms underlying de novo and acquired ER+/PR- breast cancer remain poorly defined(1). Thus, elucidation of the molecular basis of ER+/PR- breast tumor development has the potential to reveal new therapeutic targets in the treatment, or even prevention, of the resistance to anti-estrogen therapy in patients with breast cancer(2, 3). TIP30 is a human cellular 30kDa protein that was purified as a HIV-1 Tat interacting protein (4)and is expressed in various tissues in humans and mice(4, 5). Using genetically-engineered mouse models generated in our laboratory, we have demonstrated that *Tip30* deletion results in development of ductal hyperplasia and tumors in mouse several tissues (6, 7). Recently, we made novel observations that *Tip30* deletion accelerates mammary tumorigenesis induced by MMTV-Neu oncogene and mammary tumors consisting of ER-positive and PR-negative (ER+/PR-) luminal epithelial cells. This project is to study the molecular mechanism(s) underlying ER+/PR- breast tumorigenesis. Specifically, we will determine genetic and epigenetic alterations in the initiation and progression of ER+/PR- mammary tumors arising in *Tip30*^{-/-}/MMTV-neu mice; and we will also evaluate IGF-I and Wisp-2 as potential therapeutic targets for ER+/PR- mammary tumors developed in *Tip30*^{-/-} MMTV-neu mice. Results generated during the first year indicate that *Tip30* loss accelerates ER+/PR- mammary tumors in MMTV-Neu mice through EGF and IGF-1 mediated pathways.

Body:

Task 1. Determine specific genetic and epigenetic alterations in the initiation and progression of ER+/PR- mammary tumors arising in *Tip30*^{-/-}/MMTV-neu and *Tip30*^{+/-}/MMTV-neu mice. We have completed the proposed experiments in Task 1; a and b, and most of experiments in Task 1 d, which were proposed to complete in the first year. We have demonstrated that *Tip30* loss accelerated mammary tumorigenesis in MMTV-Neu mice (unpublished data). In order to further characterize mammary tumors developed from these mice, we have generated a cohort of MMTV-neu/ *Tip30*^{+/+}, MMTV-neu/ *Tip30*^{+/-} and MMTV-neu/ *Tip30*^{-/-} mice. We have been monitoring these mice for the development of mammary tumors and collected mammary tumors that developed in these mice for pathological analysis and further investigations. In order to determine expression pattern of ER α , PR-A and PR-B proteins in these mammary tumors and their adjacent mammary tissues, the tumors were subjected to immunofluorescence staining with antibodies specific for ER, PR-A and PR-B. The tumor cells in all seven *Neu*⁺/*Tip30*^{-/-} tumors examined were ER α positive and PR (PR-A and PR-B) negative (ER+/PR-) (table 1). The tumor cells from six of seven *Neu*⁺/*Tip30*^{+/+} tumors examined were both ER α and PR negative (ER-/PR-) (Table 1). In addition, we observed that the adjacent mammary glands contained ER-positive and PR-A-positive ductal cells in both *Neu*⁺/*Tip30*^{-/-} and *Neu*⁺/*Tip30*^{+/+} tumors while no PR-B-positive ductal epithelial cells were detected. The antibodies for PR used in immunofluorescence analysis are able to detect both PR-A and PR-B. This data suggests that *Neu*⁺/*Tip30*^{-/-} female mice spontaneously develop ER+/PR- mammary tumors and *Tip30*^{-/-} spontaneously develop ER+/PR+ or ER+/PR- mammary tumors. Moreover, some of these tumor

tissues were used for making RNA probes for microarray analysis and the establishment of tumor cell lines in Task1d and Task2.

Table 1. ER and PR (A,B) expressions in murine mammary tumor

Animal No.	N	Tip30	ER α	PgRA	PgRB
648	+	-/-	+	-	-
942	+	-/-	+	-	-
924	+	-/-	+	-	-
923	+	-/-	+	-	-
1281	+	-/-	+	-	-
1288	+	-/-	+	-	-
1278	+	-/-	+	-	-
634	+	+/-	-	-	-
736	+	+/-	+	-	-
743	+	+/-	-	-	-
747	+	+/-	+	-	-
906	+	+/-	+	-	-
933	+	+/-	-	-	-
951	+	+/-	+	-	-
961	+	+/-	-	-	-
1131	+	+/-	-	-	-
1764	+	+/-	-	-	-
733	+	+/+	-	-	-
762	+	+/+	+	-	-
1047	+	+/+	-	-	-
1760	+	+/+	-	-	-
2-8-08-1	+	+/+	-	-	-
2-8-08-2	+	+/+	-	-	-
2-8-08-3	+	+/+	-	-	-
2-8-08-4	+	+/+	-	-	-

To identify genetic alterations in regulatory pathways and gene expression that would explain the observed phenotypes, we performed an unbiased microarray analysis to identify the genes differentially expressed between *Neu+/Tip30^{-/-}* and *Neu+/Tip30^{+/+}* tumors using the GeneChip® Mouse Gene 1.0 ST Array (Affymetrix) that contains 28,863 mouse genes and offers whole-transcript coverage. We found that 538 genes were changed more than 2-fold, which includes 181 genes were upregulated and 357 genes were downregulated. These genes are involved in ion and protein transportation, cell adhesion, cell proliferation and apoptosis signaling pathway. Ingenuity pathway analysis of altered gene profiles revealed that the top cancer-associated pathways affected by Tip30 deletion in Neu+ mammary tumors are cAMP-mediated signaling, EGF signaling, IGF signaling and PI3K/AKT signaling and G-protein coupled receptor signaling. These results are consistent with our previous findings that Tip30 loss increases expression of two growth factors, IGF-1 and Wisp2, in mammary epithelial cells. In addition, these results also implicate that Tip30 loss may accelerate an increased activation of Akt that is a common downstream target in these growth factor mediated signaling pathways.

Task 2. Evaluate IGF-I and Wisp-2 as potential therapeutic targets for ER+/PR- mammary tumors developed in *Tip30*^{-/-} MMTV-Neu mice. We have completed Task2 a and b and portions of Task2 c. Given our previous observation that expression of IGF-1 and Wisp-2 was elevated in *Tip30*^{-/-} mammary epithelial cells (8), we examined IGF-1 and Wisp-2 expression in the tumors from *Neu*⁺/*Tip30*^{-/-}, *Neu*⁺/*Tip30*^{+/-}, and *Neu*⁺/*Tip30*^{+/+} mice with IHC analysis. Figure 1 shows in a representative comparison that the level of IGF-1 protein in *Neu*⁺/*Tip30*^{-/-} tumors (scored as ++) appears to be higher than that in *Neu*⁺/*Tip30*^{+/-} tumors (scored as +); IHC staining of IGF-1 and Wisp2 in the tumors are summarized in Table 2. We also used qRT-PCR to measure the mRNA levels of IGF-1 and Wisp2 in four mammary tumors (data not shown). These results indicate that IGF-1 and Wisp2 expression are increased in *Neu*⁺/*Tip30*^{-/-} tumors




Fig.1. IGF-1 expression in mammary tumors. Paraffin sections of tumors from mice with the indicated genotypes were stained with anti-IGF-1. Brown stain indicates IGF-1 protein. Panel A: +; Panel B: ++.

Table 2. Immunohistochemical analysis of IGF-1 and Wisp2

Animal No.	Tip30	ERα	PR(A+B)	IGF-1	WISP-2
648	-/-	+	-	++	+
942	-/-	+	-	++	++
924	-/-	+	-	++	++
923	-/-	+	-	++	++
634	+/-	-	-	+	+
736	+/-	+	-	++	++
743	+/-	-	-	-	-
747	+/-	+	-	+	-
906	+/-	+	-	+	+
933	+/-	-	-	+	-
951	+/-	+	-	+	++
961	+/-	-	-	+	+
1131	+/-	-	-	+	+
1764	+/-	-	-	+	+
733	+/+	-	-	+	-
762	+/+	+	-	+	+
1047	+/+	-	-	-	+
1760	+/+	-	-	+	+

Key research Accomplishments:

1. Our data demonstrates that Tip30 loss accelerates ER +/PR- mammary tumors in MMTV-Neu mice.
2. Our data suggests that ER+/PR- mammary tumors arising in *Tip30*-null/MMTV-neu mice exhibit increased activation of EGF and IGF-1 pathways.

Reportable outcomes:

1. Part of this work was presented as a short talk at “Midwest Breast Cancer Research Symposium” held at the University of Iowa from July 17 – 19, 2009.

2. Chengliang Zhang, Isamu Hoshino, Mikito Mori, Jill Pecha and Hua Xiao., The mechanism and role of TIP30 in mammary tumorigenesis. Midwest Breast Cancer Research Symposium. 2009. Abstract 32; pg 43.

3. A NIH RO1 grant application entitled “the role of a tumor suppressor in mammary tumorigenesis” is submitted partly based on work supported by this award

Conclusions: Our data suggest that Tip30 loss accelerates ER+/PR- mammary tumors in MMTV-Neu mice through EGF and IGF-1 mediated pathways.

References:

1. Arpino G, Weiss H, Lee AV, et al. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. *J Natl Cancer Inst* 2005;97:1254-1261.
2. Goss PE, Ingle JN, Martino S, et al. Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17. *J Clin Oncol* 2007;25:2006-2011.
3. Ponzoni R, Montemurro F, Maggiorotto F, et al. Clinical outcome of adjuvant endocrine treatment according to PR and HER-2 status in early breast cancer. *Ann Oncol* 2006;17:1631-1636.
4. Xiao H, Tao Y, Greenblatt J, Roeder RG. A cofactor, TIP30, specifically enhances HIV-1 Tat-activated transcription. *Proc Natl Acad Sci U S A* 1998;95:2146-2151.
5. Shtivelman E. A link between metastasis and resistance to apoptosis of variant small cell lung carcinoma. *Oncogene* 1997;14:2167-2173.
6. Ito M, Jiang C, Krumm K, et al. TIP30 deficiency increases susceptibility to tumorigenesis. *Cancer Res* 2003;63:8763-8767.
7. Pecha J, Ankrapp D, Jiang C, et al. Deletion of Tip30 leads to rapid immortalization of murine mammary epithelial cells and ductal hyperplasia in the mammary gland. *Oncogene* 2007;26:7423-7431.

8. Pecha J, Ankrapp D, Jiang C, et al. Deletion of Tip30 leads to rapid immortalization of murine mammary epithelial cells and ductal hyperplasia in the mammary gland. *Oncogene* 2007.